Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664740 | 0.94 | SMN1; SMN2 (0.34) | ESR2SMN1; SMN2 | |
| SCHEMBL1177140 | 0.92 | SMN1; SMN2 (0.33) | ESR2SMN1; SMN2 | |
| SCHEMBL287483 | 0.88 | ESR2 (0.34) | ESR2 | |
| SCHEMBL136340 | 0.88 | — | — | |
| SCHEMBL19293693 | 0.83 | — | — | |
| SCHEMBL428515 | 0.81 | — | — | |
| SCHEMBL294945 | 0.81 | — | — | |
| SCHEMBL428337 | 0.79 | ESR2 (0.38) | ESR2SMN1; SMN2 | |
| SCHEMBL7366794 | 0.76 | NEK2 (0.35) | — | |
| SCHEMBL417593 | 0.76 | CYP11B2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191441-B1 | NOVEL PROCESS FOR PREPARATION OF SPIRO[2.5]OCTANE-5,7-DIONE AND SPIRO[3.5]NONANE-6,8-DIONE | BOEHRINGER INGELHEIM INT TRADING SHANGHAI CO LTD (CN) | 2020-02-19 | — | — | EP | claimed |
| US-10131618-B2 | Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-20 | — | — | US | claimed |
| US-20180179142-A1 | Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione | BOEHRINGER INGELHEIM INT (DE) | 2018-06-28 | — | — | US | claimed |
| US-20170247315-A1 | NOVEL PROCESS FOR THE PREPARATION OF SPIRO[2.5]OCTANE-5,7-DIONE AND SPIRO[3.5]NONANE-6,8-DIONE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-31 | — | — | US | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4077334-B1 | FUROINDAZOLE DERIVATIVES | BAYER AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-1017659-B1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1434581-A1 | 3- HYDROXY-(-4-TRIFLUOROMETHYLPHENYL)-METHYL-7-SPIROCYCLOBUTYL-5,6,7,8-TETRAHYDROQUINOLIN-5-OL DERIVATIVES AND THE USE OF THE SAME AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | Bayer HealthCare AG (DE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003028727-A9 | 3-`HYDROXY-(-4-TRIFLUOROMETHYLPHENYL)-METHYL-7-SPIROCYCLOBUTYL-5,6,7,8-TETRAHYDROQUINOLIN-5-OL DERIVATIVES AND THE USE OF THE SAME AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | BAYER AG (DE) | 2003-11-13 | — | — | WO | disclosed |
| US-6586613-B1 | Compounds such as 5-(tert-butyldimethylsiloxy)-7,7-dimethyl -4(4-fluorophenyl)-3-(hydroxy-(4-trifluorophenyl)-methyl)-2-isopropyl -5,6,7,8-tetrahydronaphthalene, used as antagonists for cholesteryl ester transferase protein; hyperlipemia | BAYER AKTIENGELLSCHAFT (DE) | 2003-07-01 | — | — | US | disclosed |
| WO-2003028727-A1 | 3-`HYDROXY-(-4-TRIFLUOROMETHYLPHENYL)-METHYL-7-SPIROCYCLOBUTYL-5,6,7,8-TETRAHYDROQUINOLIN-5-OL DERIVATIVES AND THE USE OF THE SAME AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-04-10 | — | — | WO | disclosed |
| EP-1017659-A1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER AG (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014174-A1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | ESR2 1381/4885SMN1; SMN2 4374/4885 |
| US-20180179142-A1 | Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione | DHPS, FASTKD5, CYP3A5 | ESR2 1106/4885SMN1; SMN2 2651/4885 |
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | CETP, MTTP, HDLBP | ESR2 900/4885SMN1; SMN2 4878/4885 |
| US-20170247315-A1 | NOVEL PROCESS FOR THE PREPARATION OF SPIRO[2.5]OCTANE-5,7-DIONE AND SPIRO[3.5]NONANE-6,8-DIONE | DHPS, FASTKD5, CYP3A5 | ESR2 1106/4885SMN1; SMN2 2651/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | ESR2 653/4885SMN1; SMN2 744/4885 |
| US-10131618-B2 | Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione | DHPS, FASTKD5, CYP3A5 | ESR2 915/4885SMN1; SMN2 2440/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | ESR2 2924/4885SMN1; SMN2 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.